MF patient brochure NL
MF patient brochure FR
PARADIGM-HF
Summary:
The PARADIGM-HF study on systolic heart failure with 8,399 patients in NYHA class II-IV. 2,3...
Twitter Linkedin Facebook Pinterest Google plusSafety Profile
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Twitter Linkedin Facebook Pinterest Google plusIndications
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Twitter Linkedin Facebook Pinterest Google plusDosing
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Twitter Linkedin Facebook Pinterest Google plusReimbursement / eHealth
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Twitter Linkedin Facebook Pinterest Google plusMechanism of Action
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Twitter Linkedin Facebook Pinterest Google plusPatient Resources
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Twitter Linkedin Facebook Pinterest Google plus